logo.jpg
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
04. Dezember 2019 00:45 ET | ImCheck Therapeutics SAS
-- Bpifrance and Pfizer Ventures co-led international investor syndicate -- Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class...